Prudential Financial’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$81.4K Buy
26,525
+11,760
+80% +$36.1K ﹤0.01% 2256
2025
Q4
$52.6K Sell
14,765
-2,970
-17% -$11K ﹤0.01% 2145
2025
Q3
$61.9K Buy
+17,735
New +$60.8K ﹤0.01% 2319
2024
Q2
Sell
-23,800
Closed -$37.6K 2789
2024
Q1
$37.6K Hold
23,800
﹤0.01% 2616
2023
Q4
$48.6K Buy
23,800
+10,800
+83% +$18.7K ﹤0.01% 2555
2023
Q3
$18.2K Buy
+13,000
New +$13.5K ﹤0.01% 2574

Other funds holding STLN

Prudential Financial's STLN Position: Q1 2026 in Review

Prudential Financial increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 80% in Q1 2026, buying an estimated $36.1K and bringing the position to 26,525 shares worth $81.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2256.

Prudential Financial first reported a position in STLN in Q3 2023 and has held it in 6 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Prudential Financial held 26,525 shares of Starling Oncology Institute, Inc. Common Stock worth $81.4K as of Q1 2026.
  • Prudential Financial bought 11,760 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $36.1K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #2256 holding.
  • Prudential Financial first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2023 and has held it in 6 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.